Glenmark Pharmaceuticals Ltd (Glenmark) manufactures, develops and markets branded and generic formulations, and OTC products. Its formulation business spans across various geographies, including India, the US, Europe, Latin America and rest of the world. The company provides contract development and manufacturing operations services to various multinational and specialty pharmaceutical companies. It is also involved in the manufacture of active pharmaceutical ingredients (API).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Glenmark's R&D endeavors to develop innovative products in the areas of oncology and inflammation disorders; including respiratory and dermatology therapies. Its major pipeline products include GRC 54276 for the treatment of solid tumors is in Phase I clinical trials; GRC 39815, a new chemical entity intended for the treatment of chronic obstructive pulmonary disorder, is in Phase I trials; and GRC 54276 intended for the treatment of solid tumors which is in Phase I clinical trials. The company has formulation R&D center in Taloja, which carries out the development of cost-effective and patent-driven generic formulations; R&D center in Mahape, for the discovery and development of new chemical entities (NCEs); and a R&D center in Sinnar, which carries out the research of specialty and branded formulations for global markets. It has four R&D facilities to conduct its API operations and 10 facilities for formulation operations. In FY2023, the company spent INR12,500.3 million on R&D expenditure, which as a percentage of revenue stood at 9.6%.